English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Grounding Tricks That Actually Work Before a Plant Medicine Ceremony
The hour before an ayahuasca ceremony is a strange kind of quiet. You've done the dieta, you've written your intention, you've maybe hugged a stranger who's about to become your ceremony neighbor for the night — and then your nervous system decides it would like to leave the building. Heart racing. Jaw locked. That specific brand of anxious anticipation that no amount of deep breathing seems to touch. This is where the small tricks earn their keep. Not the big spiritual frameworks. Not the philosophy. The little mental and physical hacks that pull you back into your body when your mind starts drafting escape routes. Everyone who spends time around ayahuasca, psilocybin, or other master plants eventually collects a personal toolkit of these — and the honest truth is that most of them are unglamorous. They work anyway. What follows is a rundown of the ones facilitators, integration coaches, and long-time ceremony sitters actually use. Some are for the moments before medicine is served. Some are for the peak of a hard passage. Some are for the raw days afterward, when integration is doing its slow work and daily life feels louder than it used to. Before we get to the toolkit — a quick word on why you need one. When you're preparing for a psychedelic experience, your body reads the situation the way it would read any other high-stakes event. Cortisol climbs. Breathing shortens. The prefrontal cortex, which normally keeps everything neatly organized, starts second-guessing every decision you've ever made about anything. None of this means something is wrong with you. It means your system is doing its job. The tricky part is that going into a ceremony already flooded with anxiety usually means a rougher first hour with the medicine. Ayahuasca in particular has a way of amplifying whatever state you bring to the mat. Come in tight, and the vine will spend a while loosening you. Come in grounded, and you tend to get to the useful material faster. So the goal of these hacks isn't to eliminate nerves — nerves before a psychedelic ceremony are entirely appropriate. The goal is to keep you from spiraling into a state that costs you the first three hours of your journey. Most anxiety is a runaway thought loop that started somewhere in the head and moved into the chest. Physical interventions short-circuit that loop faster than talking yourself down ever will. A few that actually work: The theme across all of these: give the body a bigger, more immediate signal than the anxiety is giving you. Your nervous system can only really pay attention to one thing at a time. Some of the most useful pre-ceremony work happens between the ears. Not through willpower — through small, specific redirections. One that I've watched work for people who otherwise cannot meditate: name five things you can see, four you can hear, three you can touch, two you can smell, one you can taste. The classic 5-4-3-2-1 grounding sequence. It's boring, which is exactly why it works — it occupies just enough of the thinking mind to stop the anxiety spiral without demanding any kind of spiritual composure you don't have. Another: write the worst-case scenario down. Sounds counterintuitive. Isn't. When you actually put on paper the thing you're afraid of — I'll purge and be embarrassed, I'll cry in front of strangers, I'll see something terrible — it stops rattling around your head. Ceremony participants who do this before they arrive tend to walk in noticeably calmer. And a third, which is the one I use myself: set a very small intention. Not a life-changing one. Not “reveal my purpose” or “heal my mother wound.” Something like “notice what my body is doing” or “stay curious.” Master plants respond well to small doorways. Ambitious intentions can turn into performance anxiety fast. Here's where it gets interesting. Most of the hacks that work outside ceremony don't work inside it — the medicine is stronger than your grounding technique, and trying to think your way out of a difficult passage generally makes it worse. But a few small things do help: A specific note for people considering ayahuasca for addiction, depression, or trauma work: the hardest passages are often the most important ones. This doesn't mean you should white-knuckle through terror — it means that a wave of grief, nausea, or memory that feels intolerable in the moment is often exactly the material you came for. The hacks above are for staying present with it, not for escaping it. The days after a psychedelic ceremony are their own animal. You feel raw. Small things — a rude cashier, a text from your ex, the wrong podcast — can knock you sideways in ways that would have barely registered a week earlier. This is normal. It also means integration deserves its own toolkit. A few that consistently help: The people who get the most out of plant medicine, in my experience, aren't the ones who have the most dramatic ceremonies. They're the ones who take integration seriously — who use the small hacks to protect the opening, rather than trying to sprint back into their old life on day three. None of these tricks replace the bigger work. Choosing a reputable retreat, being honest about your medications and mental health history, doing the dieta properly, having an integration plan before you leave — those matter more than any breathing technique. The hacks are the trim, not the frame. But the trim matters. A ceremony where you spent the first three hours grounded because you knew how to work with your own nervous system is a different ceremony than one where you spent those hours in a panic loop. Small tools, real difference. If you're weighing a retreat and starting to build your own toolkit, a curated selection of ayahuasca and plant medicine retreats can be explored on our marketplace here — worth a slow look rather than a quick booking. The right container is what makes the hacks work in the first place.
A Grounding Practice for a Busy Mind: Seeing, Hearing, Sensing
There's a particular kind of mental noise that shows up when you're seriously considering a plant-medicine retreat. Half research, half rumination. You're reading trip reports at 1 a.m., pricing flights to Iquitos, wondering whether ibogaine or ayahuasca might actually shift something you've been dragging around for a decade. And underneath all of that — the busy mind. The one that won't sit still long enough to hear itself think. This piece is about a small, portable grounding practice that helps with exactly that. It's not glamorous. It won't unlock a mystical download. What it will do is give your attention something honest to do when everything else feels loud — including in the weeks before a ceremony and the tender days that follow one. Anyone who's spent time around ayahuasca, psilocybin, or the broader family of master plants will tell you the same thing: the medicine is only half of it. The other half is the nervous system you bring into the room. If you arrive at a retreat with a scattered, over-caffeinated, doom-scrolled mind, you're going to spend a good chunk of your first ceremony just untangling. That's normal. It's also avoidable, at least partially, with a bit of prep work. Grounding practices are the boring backbone of psychedelic healing. Facilitators talk about set and setting, dieta and intention, but underneath all of that lives a more basic skill: being able to return to your body when your mind runs off. That's what this practice trains. And it trains it in a way that doesn't require an app, a cushion, or a spare hour. Here's the honest bit — most people who sign up for a retreat have never really meditated. They've tried, felt bad about it, and quietly stopped. That's fine. This isn't meditation in the intimidating, cross-legged, hour-a-day sense. It's a technique. A way of nudging your attention into three simple lanes and letting it rest there. The whole thing rests on rotating your awareness through three doorways of experience: what you see, what you hear, and what you feel in your body. Each doorway anchors you in the present in a slightly different way, and the movement between them keeps the mind engaged enough that it doesn't wander off into next Tuesday's meeting. Try it now if you have five minutes. If you don't, bookmark it. But five minutes is really all this asks. That's it. No mantras, no visualisations, no chakras to track. The elegance of the practice is that it uses what's already happening. You're always seeing something, hearing something, feeling something. The practice just asks you to notice. A fair question. Why is a piece on a psychedelics site talking about grounding drills? Because integration — the part everyone underestimates until they've done a retreat — depends on this skill. When you come back from ceremony carrying insights that felt luminous in the maloca but slippery on the plane home, the difference between an experience that reshapes your life and one that fades into a nice story is your capacity to return to the present. Grounding is what makes integration possible. Without it, the material dissolves. The same goes for the ceremony itself. Anyone who's sat with ayahuasca knows there are moments — usually around the two-hour mark — when the brew asks you to surrender something. Fear, grief, an old story about yourself. If your only mode of coping is thinking your way out, you'll struggle. But if you've practised dropping into sensory experience, you have another door. You can hear the icaros. You can feel the mat under your back. You can let the visions do what they came to do. Facilitators I trust often say that the people who get the most from a retreat aren't the ones with the most dramatic ceremonies — they're the ones who've built even a modest daily practice beforehand. This is a candidate for that practice. Here's how it plays out in the real arc of a plant-medicine journey. Before. In the weeks leading up to a retreat, most people oscillate between excitement and low-grade panic. You've committed money and time. You've told a few close friends and stayed vague with everyone else. Your mind is running scenarios. Practising seeing-hearing-sensing for even five minutes a day does two things: it starts to build the muscle of returning to now, and it gives your nervous system regular small doses of settling. That matters when you land in the jungle and everything is unfamiliar. During. Between ceremonies at a retreat, there's usually a lot of downtime — hammocks, journaling, the occasional cold shower. This practice is perfect filler. It's also useful during the ceremony itself, in the calmer stretches, as a way to keep an anchor thrown while the deeper currents move. After. The re-entry period is where most integration lives or dies. You've had experiences you can barely articulate, and suddenly you're back in traffic, back at your desk, back to a partner who wasn't in the room with you. The busy mind returns with reinforcements. Seeing, hearing, sensing gives you a way to pause without needing to explain yourself to anyone. This practice won't fix a serious mental health crisis. It won't replace a trained therapist or a proper integration circle. If you're carrying complex trauma, and especially if you're considering plant medicine partly because of that trauma, please put professional support in place alongside whatever you do. Grounding is a supplement, not a substitute. Also: don't judge the practice by how it feels the first time. Most people's first attempts at anything meditative feel like nothing. That's not failure — that's just what the beginning of a new attentional habit feels like. Give it two weeks of five minutes a day before deciding whether it does anything for you. Try it in different environments too. Doing this indoors, with a fridge hum and the click of a heater, produces one flavour. Doing it in a park, or on a porch at dawn, produces something else entirely. Retreat centres in the Amazon or the Andes are dense with sound and light — the practice takes on a very different quality there. Notice the contrast. It's part of the training. Grounding practices like this one are, in a way, a quiet test. If you can carve out five minutes a day to sit with your own attention, you're already doing some of the work a retreat will amplify. If you can't — or you notice fierce resistance to even trying — that's useful information too. It tells you something about what the ceremony will be asking of you. None of this is meant to talk you into or out of anything. Plant medicine is a serious decision and deserves a serious research process. But the readiness question is real, and it's answered in small daily moves more than in dramatic ones. If, after sitting with this for a while, you find yourself genuinely ready to look at what's out there, a curated selection of ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, come back to seeing, hearing, sensing when the mind gets loud. It's older than any tradition and simpler than any technique. And it's always available — which is more than can be said for most things worth having.
What Positive Mental Health Actually Means for People Considering Plant Medicine
Most people who start looking into an ayahuasca retreat aren't chasing enlightenment. They're tired. Tired of the low-grade depression that never quite lifts, the drinking that started as fun and became a fixture, the trauma that keeps rerouting their lives in small ugly ways. They want to feel better — and they've noticed that “not depressed anymore” isn't quite the same thing as “alive.” That gap — between the absence of illness and the presence of something worth calling flourishing — is what researchers have been trying to pin down for decades. And a recent international consensus finally put some structure around it. If you're considering plant medicine or a psychedelic retreat, this framework is genuinely useful. It gives you a way to think about what you're actually hoping to move toward, not just what you're trying to escape. For most of the 20th century, psychiatry ran on a simple assumption: mental illness and mental health sit at opposite ends of one line. Reduce symptoms, and health improves. It's clean, it's intuitive, and it turns out to be wrong — or at least badly incomplete. Researchers like Corey Keyes reframed the whole thing as two separate continua. One tracks mental illness (present or absent). The other tracks positive mental health, running from languishing to flourishing. The important part: those two lines move independently. You can have zero clinical symptoms and still feel hollow — no purpose, no real connection, no vitality. You can also be actively wrestling with depression and still have deep relationships, meaningful work, and a functioning sense of self. Anyone who has sat across from someone freshly out of a ceremony knows this intuitively. The medicine may have knocked out a symptom cluster — the intrusive thoughts, the cravings, the numbness — but the person still has to build a life worth staying sober for. Symptom reduction is the floor. Flourishing is the actual project. In 2025, a research team ran a structured Delphi process — a rigorous method for building expert consensus — with 122 specialists across 11 disciplines. They built on an earlier review of 155 different measures of well-being, which had originally identified 410 overlapping dimensions and boiled those down to 21 candidate themes. After three rounds of expert rating and refinement, 19 dimensions cleared the 75% agreement threshold. What emerged is not a theory. It's a taxonomy — a classification system with shared language. That distinction matters. Instead of arguing about whether Ryff's model beats Diener's or Deci and Ryan's, researchers and clinicians now have a common vocabulary. And the framework is explicitly multidimensional: you're not supposed to max out every category. People flourish differently depending on values, culture, life stage, and circumstance. Six dimensions cleared the highest bar, above 90% expert agreement: The other 13 dimensions — things like resilience, vitality, self-esteem, sense of safety, engagement, personal growth — landed between 75% and 89% agreement. All of them count. None of them, on their own, is enough. Here's where the taxonomy gets practically interesting. In the final Delphi round, experts were asked whether each dimension functions more as a driver (something that produces flourishing) or an outcome (a result of it). Autonomy and a sense of safety leaned toward the driver side. Happiness and life satisfaction leaned toward the outcome side. That's not a semantic distinction — it changes what you should actually work on. Think about it this way: if you go into an ayahuasca ceremony hoping to “feel happier,” you're chasing an outcome. Outcomes don't respond well to being chased directly. What ayahuasca and other master plants often do — when the container is good and the integration is real — is nudge the drivers. People come out with a clearer sense of what they actually value (autonomy). They report feeling safer in their own bodies for the first time in years (sense of safety). They see their own story differently and can hold it without flinching (self-acceptance). The happiness, when it comes, tends to arrive as a byproduct. This is why the retreats that work bother with things like preparation calls, dieta protocols, one-on-one integration sessions, and follow-up months later. They're not selling you a peak experience. They're trying to shift the drivers so the outcomes have somewhere to grow. Before you book anything, it's worth sitting down honestly and asking which of these 19 dimensions feel thin in your life right now. Not which ones you'd like to brag about — which ones actually feel underfed. This is more useful than the vague “I want to heal” framing that most people arrive with. A few practical prompts: Whatever you find, bring it into your conversation with any retreat you're vetting. A serious facilitator will want to hear it. They'll ask about your history, your medications, your intentions, your support system back home. If they don't — if they're just taking your credit card and telling you the jungle will handle the rest — that's a red flag. The taxonomy is useful here too as a diagnostic: retreats that only talk about “bliss” and “transformation” are pitching an outcome. Retreats that talk about integration, community, values clarification, and long-term work are aimed at drivers. Ayahuasca, psilocybin, ibogaine, San Pedro — these medicines don't manufacture flourishing. What they seem to do, in the best cases, is dissolve some of the obstacles to it. The ruminative loop that kept you stuck. The addictive pattern that had colonized your evenings. The trauma memory you couldn't approach without shutting down. When those obstacles loosen, the underlying drivers — meaning, connection, autonomy — often have room to breathe again. But the medicine doesn't do the building. That part is yours, and it happens in the boring weeks and months after the ceremony ends. This is why people who treat a retreat as a one-shot fix are often disappointed six months later, while people who treat it as the opening move in a longer game tend to see actual change. The taxonomy gives you a map for that longer game. You know what you're trying to grow. You know it's more than one thing. You know some pieces will come first and others will follow. For readers who want to take this further, a range of curated plant-medicine and psychedelic retreats can be browsed on our marketplace here — worth exploring alongside your own honest inventory of which dimensions of flourishing you're actually trying to build.
Eli Lilly Buys AtaiBeckley for $3.8B: What It Means for 5-MeO-DMT and Psychedelic Medicine
Something significant just happened in the psychedelic world, and if you're someone who's been quietly researching plant medicine — maybe eyeing a 5-MeO-DMT retreat, maybe wondering whether the whole field is about to change — you should know about it. Eli Lilly, the largest pharmaceutical company on the planet, has agreed to acquire AtaiBeckley for as much as $3.8 billion. That's not a typo. Big Pharma has officially placed its biggest chip on the psychedelics table. AtaiBeckley's lead compound is an intranasal formulation of 5-MeO-DMT — the same molecule found in the venom of the Sonoran Desert toad and in certain plants used ceremonially across South America. Their candidate, BPL-003, is heading into Phase 3 trials for treatment-resistant depression. The deal also includes VLS-01, a DMT-based candidate. And the price tag makes every previous psychedelic acquisition look modest. Lilly is paying $6.75 per share upfront in cash for all outstanding shares, plus up to $2.50 per share in milestone payments tied to development and regulatory approval. Do the math and you get roughly $2.8 billion in cash on day one, with another billion or so in potential milestone-based payouts depending on how things unfold in the clinic and at the FDA. The milestones are structured like this: a payout when VLS-01 hits Phase 3, another when BPL-003 secures FDA approval and DEA rescheduling, and a third when VLS-01 does the same. Each has a time limit — four, five, and seven years respectively. Miss the window, no bonus. To put the scale in perspective: earlier this year Otsuka acquired Transcend Therapeutics for up to $1.225 billion. Late last year, AbbVie picked up Gilgamesh's bretisilocin program for up to $1.2 billion. The AtaiBeckley deal is roughly three times the size of either. It's the largest psychedelic buyout ever, and it's not close. You might be thinking: cool, big finance news, but I'm trying to decide whether to sit in ceremony in Mexico next spring. What does a pharma deal have to do with me? More than you'd think. When a company like Lilly moves in, a few things start happening in parallel. Clinical trials accelerate. Regulatory conversations get serious. Insurance-covered psychedelic-assisted therapy inches closer to reality in the United States. And — this is the part that matters most for the retreat world — the cultural conversation shifts. Substances that were considered fringe five years ago start showing up in mainstream psychiatric discussions. That has knock-on effects for legality, for public perception, and eventually for how easy or hard it is to legally access these experiences. There's also a quieter effect. As pharma standardises dosing, formulation, and clinical protocols, some seekers will still want the traditional container — the shaman, the maloca, the icaros, the community — that no clinic can replicate. Others will prefer the medicalised route. Both paths are widening. The retreat world isn't going away; it's about to sit alongside a very different offering. Since Lilly's press release conspicuously avoided the word "psychedelic" (which tells you something about how the messaging will be shaped going forward), let's be plain about what this molecule is. 5-MeO-DMT is a naturally occurring tryptamine. It's found in the parotid gland secretions of the Bufo alvarius toad, in the bark of certain Amazonian trees, and in the seeds of Anadenanthera plants used in traditional Yopo snuff. In ceremonial contexts, it's often called "the God molecule" — not because anyone's making a theological claim, but because participants routinely describe experiences of ego dissolution and unity so total that ordinary language fails. The experience is short. Typically five to twenty minutes at peak, compared to ayahuasca's four to six hours. But short doesn't mean easy. 5-MeO-DMT is often described as more intense than any other psychedelic, and it demands rigorous preparation, skilled facilitation, and thoughtful integration afterward. This isn't a substance to approach casually or alone. The response within the psychedelic community has been split, and honestly, that's how it should be. This kind of deal is genuinely double-edged. If you're actively researching a psychedelic retreat, here's the honest read. Nothing about today's news changes what you're weighing this week. 5-MeO-DMT retreats — most of them working with synthetic material rather than toad secretions these days, for ethical and ecological reasons — still operate in the same legal gray zones they always have. Same with ayahuasca, psilocybin, and ibogaine retreats. What might shift over the next three to five years is the broader landscape. Expect more clinical trials recruiting participants. Expect more state-level regulatory experiments (Oregon and Colorado are already there for psilocybin). Expect more mainstream media coverage that alternates between breathless enthusiasm and moral panic — often in the same publication. For the individual decision you're making right now, the fundamentals haven't changed. If you're considering plant medicine for depression, addiction, trauma, or a stuck life pattern, the questions to ask a retreat are the same ones that mattered last year: A pharma acquisition doesn't answer any of these. Only the retreat can. Zoom out for a moment. Twenty years ago, the idea that a compound like 5-MeO-DMT would be entering Phase 3 trials backed by Eli Lilly would have sounded absurd. Ten years ago, MAPS was still fighting for MDMA to be taken seriously. Today, the mainstream psychiatric establishment is quietly rearranging itself around psychedelic-assisted therapy. None of this means the medicalised path is the right one for everyone. Plenty of people find deeper healing in a traditional ceremonial setting than they ever would in a clinical suite with fluorescent lighting and a clipboard. The master plants — ayahuasca, San Pedro, iboga, psilocybin mushrooms, and yes, 5-MeO-DMT when treated with appropriate reverence — have been teaching humans about themselves for thousands of years, and they'll keep doing so regardless of what happens on the Nasdaq. But it's fair to acknowledge that we're living through a genuine turning point. The question isn't whether psychedelic medicine will become part of mainstream mental health care — it's how, on what terms, and who benefits. Deals like this one shape those answers. If you've been sitting with the question of whether a retreat is right for you, this news is neither a green light nor a red one. It's context. Take it in, keep researching, and trust your own timing. For readers who want to explore what's actually available right now, a curated selection of 5-MeO-DMT, ayahuasca, and other plant-medicine retreats can be browsed on our marketplace here.
What Psychedelics Actually Feel Like: An Honest Look Inside the Experience
Ask ten people what a psychedelic trip feels like and you’ll get ten wildly different answers. Some talk about geometric visuals dancing behind their eyelids. Others describe crying for three hours over something their father said in 1997. A few just shrug and say, “I felt like myself, but more.” None of them are lying. That’s the strange thing about psychedelics and ayahuasca — the experience refuses to sit still long enough to be described cleanly. If you’re considering a retreat, you’ve probably already watched the documentaries and read the Reddit threads. And you’ve probably noticed that most of them either oversell the mystical fireworks or underplay how physically strange the whole thing can get. So let’s talk about what actually happens in the body and mind when you drink the brew, eat the mushrooms, or sit down for a San Pedro ceremony. Not the marketing version. The real one. Almost every psychedelic experience begins with a peculiar limbo. You’ve taken the medicine. Nothing’s happening. You start wondering if you got a weak batch, or if you’re somehow immune, or if this is going to be the world’s most expensive nap. Facilitators call this the doubt window, and it’s so common it’s basically a rite of passage. Then, quietly, something shifts. It’s not a curtain being pulled back — it’s more like the room’s volume changing by two clicks. Sounds get a little rounder. Your body feels a bit heavier, or lighter, depending on the medicine. With ayahuasca, most people notice a warmth in the stomach and a metallic taste that just won’t leave. With psilocybin, it’s often a giggly restlessness and a sudden interest in the ceiling. With ibogaine, it’s a low buzzing hum that seems to come from inside your bones. None of this feels dramatic yet. That’s the point. Psychedelics don’t kick down the door — they let themselves in through a window you didn’t know was open. Here’s something people rarely mention: psychedelic experiences are deeply physical. Long before you’re contemplating the nature of the universe, you’re dealing with a body that suddenly feels unfamiliar. With ayahuasca specifically, purging is part of the deal. That means vomiting, sometimes crying, sometimes diarrhea, sometimes shaking. Shamans in the Amazon consider the purge medicinal — the body releasing what the mind has been holding. It’s not pleasant, but participants often report an odd relief afterwards, as if something they didn’t know they were carrying just left the building. If a retreat tells you their ayahuasca doesn’t make anyone purge, be suspicious. That’s not a feature. That’s marketing. Other medicines have their own physical signatures: The physical stuff matters because it’s where the resistance lives. Fighting the body sensations is what turns a difficult trip into a truly bad one. Learning to sink into them — even the uncomfortable ones — is half the work. This is the part that’s hardest to translate. Language was built for the ordinary world, and psychedelic states aren’t ordinary. But a few patterns show up again and again in what people describe after retreats. The first is a loosening of the internal narrator. That constant inner voice — the one running commentary on your day, your worries, your grocery list — gets quieter. Sometimes it goes silent completely. In its place, you notice things you hadn’t noticed in years. The specific texture of a memory. The way a piece of music actually feels rather than just sounds. The fact that you’ve been holding your shoulders up around your ears since roughly 2019. The second is emotional access. Feelings that were locked in a filing cabinet somewhere suddenly walk right into the room. Grief you postponed. Anger you rationalized. Tenderness you thought you’d outgrown. This is why plant medicine work is so often paired with trauma healing and addiction recovery — the medicine doesn’t create these feelings, it just removes the door you’d been holding shut. The third is what people clumsily call “ego dissolution.” At higher doses, the sense of being a distinct self can loosen or, in stronger experiences, vanish. This isn’t as terrifying as it sounds when you’re prepared. Most participants describe it as peaceful, even funny — the realization that the self you’ve been defending so hard your entire life is more of a costume than a fortress. Depends on the medicine and the dose. Ayahuasca visuals are famous for a reason — geometric patterns, jaguars, serpents, city-like structures made of light. But they’re not universal. Plenty of experienced drinkers report mostly emotional or bodily journeys with minimal visual content, especially in earlier ceremonies. Psilocybin tends to produce softer, more organic visuals: breathing walls, faces in wood grain, colors that seem lit from inside. San Pedro is often described as visually gentle but emotionally vast. Ibogaine produces something closer to a waking dream — long, cinematic replays of memory, sometimes decades of your life running in reverse. Here’s the honest bit: if you’re signing up primarily for the visual show, you’ll probably be disappointed. The visuals are wallpaper. The real event is what the visuals are pointing at — a feeling, a memory, a question you’ve been avoiding. A four-to-six-hour ayahuasca ceremony isn’t four to six hours of revelation. There are long stretches where nothing much is happening. You’re lying on a mat. You’re slightly uncomfortable. You’re wondering when the next wave will come, or whether you should get up and go to the bathroom, or whether the person two mats over is okay because they’ve been groaning for a while. These stretches are part of the medicine. They’re where restlessness lives, and restlessness is data. What you fidget about in ceremony is often exactly what you fidget about in life. Facilitators worth their salt won’t rescue you from these moments — they’ll let you sit in them, because sitting is the whole practice. Reading trip reports is fine. Watching documentaries is fine. But nothing prepares you like doing the practical work in the weeks before ceremony. A few things that reliably help: Here’s something the retreat brochures underplay: the trip isn’t the healing. The trip is the diagnostic. The healing happens in the ordinary weeks that follow, when you have to actually apply what you saw. People come back from ayahuasca or psilocybin retreats glowing. Two weeks later, some of them are back to their old patterns because they never did the integration work — journaling, therapy, community, small daily practices. The plant medicine cracked the door open. Walking through it is on you. This is why serious retreats now include integration calls, aftercare groups, and referrals to therapists trained in psychedelic integration. If a retreat you’re looking at doesn’t mention aftercare, that’s worth asking about before you book. The other thing worth saying honestly: not every experience is transformational. Some people have a challenging night and don’t receive obvious insight. Some feel like nothing much happened at all. Both are legitimate outcomes, and both are often followed by unexpected shifts weeks or months later, once the mind has finished digesting whatever it was shown. If any of this resonates and you’re starting to think seriously about a ceremony, a wide range of vetted ayahuasca and plant-medicine retreats can be explored on our marketplace here. Read the descriptions carefully, ask questions before you book, and trust the discomfort of not choosing quickly — that hesitation is part of the preparation too.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Psychedelics and Emotions: What Plant Medicine Actually Does to Feeling
Ask ten people who've sat through an ayahuasca ceremony what it felt like emotionally, and you'll get ten different answers. One will tell you they wept for four hours over a grandmother they hadn't thought about in a decade. Another will describe a bottomless, laughing joy. A third will say they felt nothing at all — until three days later, when they burst into tears at a grocery store checkout. Psychedelics do something strange to emotions, and researchers are only starting to map what. If you're weighing a plant medicine retreat, this matters. The stories you hear online tend to skew toward the extremes — the miraculous breakthrough or the harrowing dark night. The emotional middle, where most of the actual work happens, gets less airtime. So let's talk about what the research and the reports actually suggest about psychedelics and feeling, and what a reasonable person considering ayahuasca, psilocybin, or another master plant should know before they book. Classical psychedelics — ayahuasca, psilocybin, LSD, mescaline, DMT — all touch the serotonin 2A receptor. That's a big part of why they change perception. But the more interesting effect, for people considering these substances therapeutically, is what happens to emotional processing. Brain imaging studies over the past several years have shown that psychedelics reduce activity in the amygdala's fear response while simultaneously increasing connectivity between regions that don't normally talk much. The wall between thought and feeling gets thinner. In practical terms: a memory you've kept at arm's length for twenty years suddenly has full emotional weight again. A resentment you thought you'd worked through turns out to still be sitting in your chest. Grief you never let yourself finish shows up ready to be finished. This is why people describe ceremonies as feeling like decades of therapy compressed into one long night. It's not that the substance gives you new information. It gives you access to feelings that were already there. None of this is guaranteed to be pleasant. That's worth saying plainly. One study on psilocybin found that participants reported both dramatically increased positive emotions AND dramatically increased negative emotions during their sessions — often within the same trip. That squares with what facilitators have been saying for decades. A ceremony isn't emotionally one-directional. You can spend an hour in something close to ecstasy and the next hour convinced you've made a terrible mistake with your life. Here's a rough sketch of what people commonly report, though your experience may look nothing like this: The people who get the most out of a retreat tend to be the ones who don't decide in advance which of these they're hoping for. Going in wanting bliss and getting rage is a setup for disappointment. Going in curious about whatever needs to move usually goes better. The clinical research on psychedelics for mental health has been steady and, in some cases, striking. Psilocybin trials for treatment-resistant depression have produced remission rates that outperform conventional antidepressants in some studies. Ayahuasca has been studied for depression with similar directional results. Ibogaine has decades of anecdotal and clinical evidence behind its use for opioid dependence, and MDMA-assisted therapy showed strong outcomes for PTSD in phase 3 trials. The proposed mechanism, in most cases, comes back to emotions. Depression, trauma, and addiction all involve, in different ways, a stuck relationship to feeling. Depression often looks like emotional blunting — you can't access joy, but you can't fully access grief either, so nothing moves. Trauma looks like feelings frozen in place, associated with memories the nervous system won't stop guarding. Addiction, at least one common reading of it, is what people do to avoid feelings they don't believe they can survive. Psychedelics appear to temporarily loosen these patterns. The emotional gates open. What was stuck starts moving. And in the days and weeks after — this is important — the person has a window to build a different relationship with those feelings before the old patterns re-form. That window is why integration matters so much. Retreats tend to sell the ceremony. The real work is often in the two weeks after. People come home from a well-run ayahuasca retreat and find that everything feels louder for a while — colors, food, other people's moods, their own reactions. Small things that used to slide off make them cry. Old certainties feel less certain. This is normal, and it's temporary, and it's also the exact moment where lasting change either roots or doesn't. Some honest advice for that window: Not every retreat is equipped to hold someone through big emotional weather. Some are, some really aren't. If you're going in with genuine trauma, depression, or addiction history, the venue matters more than the marketing implies. Things worth asking before you send a deposit: How many facilitators are present per participant during ceremony? What's the medical screening process? What happens if someone has a psychiatric crisis mid-ceremony — do they have a plan, or do they wing it? Is there integration support included, or does it end when you get on the plane home? Do they screen out people on SSRIs, lithium, or MAOIs? (If they don't, that's a red flag — those combinations range from ineffective to genuinely dangerous.) A good facilitator will answer these questions patiently and without defensiveness. If someone gets cagey when you ask about medical safety, take it as data. The best retreats treat emotional preparation and post-ceremony support as core to what they offer, not as afterthoughts. Plant medicine is not a shortcut, and anyone selling it as one is either naive or dishonest. It can crack something open that talk therapy has been circling for years. It can give you a felt sense of possibilities your rational mind had ruled out. It can, in the right conditions, meaningfully shift depression, trauma responses, and addictive patterns. What it will not do is exempt you from the ordinary work of building a life. The feelings that come up in ceremony still have to be metabolized in daylight. The insights still have to be tested against your actual relationships, your actual work, your actual habits. People who treat a retreat as the destination often end up disappointed six months later. People who treat it as one useful intervention within a longer commitment to their own honesty tend to be the ones who look back on it as pivotal. If any of this resonates and you'd like to look at options, a curated selection of ayahuasca and plant medicine retreats can be browsed on our marketplace here. Take your time with the decision — the right retreat, at the right moment in your life, is worth more than any bargain you might find rushing into the wrong one.
Psychedelics Go Mainstream: What Lilly's $3.8B Buyout Means for Retreat-Goers
Something shifted in the psychedelics world this month, and if you're the kind of person quietly researching ayahuasca retreats at 1am — you know who you are — it's worth paying attention. Eli Lilly, one of the largest pharmaceutical companies on the planet, just agreed to buy a psychedelic drug developer for up to $3.8 billion. That's not a rounding error. That's a signal. At the same time, the FDA quietly released its final guidance for running clinical trials on psychedelics, scheduled a public meeting for September on how these therapies might actually be rolled out, and a Harvard team landed an $11 million federal grant to study ibogaine for opioid addiction. All in one week. The people who track this space for a living called it the busiest stretch in the field's history. So what does any of that have to do with you, the person weighing whether to fly to Peru, or Costa Rica, or Mexico, to sit in ceremony? More than you'd think. Let's unpack it. Lilly's target is AtaiBeckley, a developer focused on 5-MeO-DMT — the compound extracted from the Sonoran Desert toad, sometimes called bufo. It's a short, extraordinarily intense psychedelic experience, and it's been used ceremonially by underground facilitators for a decade or so. Now it's on track to become a prescription medicine, developed under FDA rules, with clinical trials and manufactured doses. The price tag matters. Up to $3.8 billion is the kind of money that ends debates about whether psychedelics are a passing wellness fad. When Lilly writes a check that size, their board has already decided this is a real category. Investment analysts, insurance companies, and regulators are all taking notes. What it doesn't mean: that your ayahuasca ceremony in the Amazon is about to become a Lilly product. Traditional plant medicines — ayahuasca, San Pedro, iboga, psilocybin mushrooms in their whole form — are unlikely to be patented and sold as pharmaceuticals. What pharma companies pursue are isolated molecules, standardized doses, and treatment protocols that fit inside a clinic visit. Two very different worlds. But those worlds are starting to talk to each other. The agency's final guidance on psychedelic clinical trials sounds boring on paper. It matters a lot in practice. Until recently, researchers running trials on psilocybin, MDMA, or DMT had to guess at what the FDA wanted to see. Now there's an actual document — how to design the studies, how to handle the therapist's role during dosing sessions, how to measure outcomes that involve, say, mystical experiences or ego dissolution. A public meeting on rollout is coming in September. That's the conversation about who prescribes these medicines, what training facilitators need, and how patients might actually access them once approved. If you've been following the MDMA-for-PTSD saga — which hit turbulence when the FDA sent it back for more data — this next phase matters. The regulators are building a road, not just approving a single drug. For someone considering a plant medicine retreat right now, here's the honest read: legal, FDA-approved psychedelic therapy in the U.S. is coming, but slowly, and it will look nothing like a jungle ceremony. It'll happen in a clinic, cost thousands of dollars, likely won't be covered by insurance for years, and won't include the community, the icaros, the dieta, or the shaman. Different medicine, different container, different results. Here's the piece that stopped me in my tracks. The National Institute on Drug Abuse — a federal agency that spent decades treating psychedelics as public enemies — just handed Harvard $11 million to study ibogaine for opioid use disorder. Ibogaine is the alkaloid from the iboga root, used traditionally in Gabon in Bwiti ceremony, and known for something remarkable: it can interrupt opioid dependence in a single dose. Not manage it. Interrupt it. People who've been through ibogaine treatment — usually in Mexico, Costa Rica, or Portugal, since it's Schedule I in the U.S. — often describe the experience as reviewing their entire life in a long, waking dream. Some emerge with cravings gone. Others relapse. It's not a miracle, and it has real cardiac risks that have killed people who weren't properly screened. But the anecdotes have been strong enough, for long enough, that even the federal government wants a rigorous answer. Why this matters for retreat-goers: You could read all this news as reassurance. Governments are studying it, pharma companies are buying it, Harvard is publishing on it — clearly plant medicine works. That's half true and half misleading. Here's the more useful frame. The mainstreaming of psychedelics does three good things for retreat-seekers. First, it raises the floor on safety. As more research comes out, more retreat centers adopt medical screening, integration support, and facilitator training that actually meets a standard. Second, it makes the conversation more honest. Your therapist back home is less likely to look at you sideways when you say you're going to sit with ayahuasca. Third, it opens legal pathways — Oregon and Colorado already have regulated psilocybin programs, and more states will follow. But there are risks in the hype too. Money flowing in attracts opportunists. Retreat centers are opening faster than qualified facilitators are being trained. Marketing has gotten slicker. Prices have climbed. And the temptation to skip the boring parts — the preparation, the dieta, the integration afterward — grows when the whole thing is framed as a product you buy rather than a practice you enter. If you're actively weighing a booking, a few things worth knowing: The news cycle will keep churning. Another pharma acquisition will happen. Another study will drop. Another state will pass a psilocybin bill. None of that changes the essential question a retreat-seeker has to sit with: is this the right medicine, in the right container, at the right moment in your life? If the answer is yes — or even a curious maybe — a range of vetted ayahuasca, psilocybin, and ibogaine retreats can be browsed on our marketplace here. Take your time. The medicine will still be there next month, and the right retreat is worth waiting for.
Harvard's $11M Ibogaine Study for Opioid Addiction: What It Actually Means
Something quietly significant just happened in the world of psychedelics and addiction research. Harvard-affiliated researchers landed roughly $11 million in federal funding to move ibogaine — the notoriously intense West African root medicine — toward its first properly sanctioned clinical trial in the United States. If you've been watching this space for a while, you know how big that sentence is. For decades, ibogaine has lived in a strange purgatory. People credit it with breaking heroin and fentanyl addictions in a single session. Others have died from it. It's legal in Mexico, illegal in the US, and quietly changing lives in clinics from Tijuana to Costa Rica. Now the National Institute on Drug Abuse — a federal agency, not a fringe advocacy group — is writing an eight-figure check to study it. That's worth paying attention to. The award is what researchers call a UG3/UH3 grant, capped at around $11 million, with an initial $2.3 million released to get things moving. The principal investigator is Joji Suzuki, a psychiatrist at Mass General Brigham and associate professor at Harvard Medical School whose lab has been poking at the edges of addiction medicine for a while now — GLP-1 drugs, psychedelics, the whole toolkit that mainstream psychiatry has largely ignored until recently. The plan unfolds in three stages. First: secure Investigational New Drug (IND) clearance from the FDA — the piece of paper that legally permits researchers to give ibogaine to human volunteers on American soil. Second: run a Phase I safety trial. Third: if the safety data looks acceptable, proceed to a Phase IIa study in people with opioid use disorder. Each stage depends on the previous one going smoothly, which in FDA-land is never a given. To put the IND question in perspective: only one ibogaine-adjacent compound has ever gotten that green light in the US, and it's noribogaine, the drug's primary metabolite, cleared earlier this year for a company called DemeRx to study at lower doses. Ibogaine itself — the full, intense molecule that people fly to Mexico for — has never been approved for a US clinical trial. If Harvard pulls it off, that's a first. If you've never read the ibogaine literature, here's the short version of why serious researchers keep coming back to it. In the underground and clinical-tourism world, ibogaine has a reputation for something no other treatment offers: interrupting opioid dependence in a single session, often with minimal withdrawal afterward. Not a taper. Not a months-long medication regimen. One long, grueling day inside your own head. People who've been through it describe a dreamlike waking state that lasts eight to twelve hours, an unflinching review of their own life choices, and — for many — a kind of neurological reset. When they wake up, the craving is gone or dramatically reduced. That's the anecdotal claim. It's been repeated by enough people, in enough places, for enough years, that scientists have stopped rolling their eyes and started asking the harder question: how? The current opioid crisis makes that question urgent. Fentanyl has broken most existing treatment models. Methadone and buprenorphine work for some people and not others. Deaths keep climbing. When a federal funding body starts writing checks for a Schedule I substance with a scary side-effect profile, it's a signal that the establishment has run out of ideas it likes better. Let's be honest about the risks, because pretending otherwise does no one any favors. Ibogaine can cause cardiac arrhythmias, specifically QT interval prolongation, and there have been deaths — mostly in unmonitored settings, often in people with undiagnosed heart conditions or other drugs in their system. Any legitimate ibogaine provider does extensive cardiac screening beforehand: ECGs, blood work, medical history. The clinics that skip this are the ones you read about in the sad news stories. Part of what the Harvard trial has to establish is a safety protocol that satisfies the FDA. That means figuring out dosing, monitoring, exclusion criteria, and rescue procedures with a rigor that underground clinics — even excellent ones — simply don't operate under. This is one of the genuine benefits of formal research: not that it validates what practitioners already know, but that it produces data solid enough to change insurance coverage, medical training, and eventually access. If you've landed on this article because you or someone you love is struggling with opioids — or alcohol, stimulants, or any of the other patterns ibogaine has been used to interrupt — here's my honest take. Federally funded research at Harvard is fantastic news for the long game. It'll probably take five to ten years before ibogaine is available as an approved treatment in a US clinic, if it ever gets there. That's a long time when you're using now. In the meantime, people are still going abroad. Reputable ibogaine clinics do exist — mostly in Mexico, Costa Rica, Portugal, and a few other jurisdictions where the legal picture allows it. The difference between a good one and a dangerous one comes down to medical staff on site, real cardiac screening, honest informed consent about risks, and — critically — an integration and aftercare plan. If a clinic promises you'll be cured in a weekend and never crave again, walk away. That's not how it works, even when it works. The other reality worth naming: ibogaine is one tool among several in the psychedelic-assisted recovery conversation. Ayahuasca has a long track record for helping people unwind patterns of substance use, particularly in traditional Amazonian settings and in centers like Takiwasi in Peru that specifically treat addiction with plant medicines. Psilocybin research at Johns Hopkins and NYU has shown real promise for alcohol and tobacco dependence. Different medicines suit different people and different problems. My suggestion, if you're reading this as someone weighing plant medicine for your own healing: don't wait for the FDA to bless something before you take your situation seriously. Also don't rush toward a Mexican clinic next week because you read a Harvard press release. What the Harvard grant tells us is that the direction of travel is real — the science is catching up to what people in the underground and traditional practitioners have been saying for a long time. The right move is usually the slow one. Learn as much as you can. Talk to people who've actually done it, not just the enthusiasts on Reddit — find the ones who've been three years out and can tell you what the year after their ceremony was actually like. Look into whether ayahuasca, psilocybin, or ibogaine (or something more traditional like therapy plus buprenorphine) fits your specific situation. Understand your own medical picture. And plan for the integration work that comes after, because that's the part almost nobody talks about at the front end. The Harvard news is a marker in a much longer road. Plant medicines are moving from the shadows into the labs, and while the pace of formal science is glacial compared to the urgency people feel, the momentum is real. If exploring a supervised plant medicine experience feels like a genuine step for you rather than a Hail Mary, a range of vetted ibogaine, ayahuasca, and psilocybin retreats focused on addiction and recovery can be browsed on our marketplace here. Take your time with the decision — this is one of those choices that rewards patience.
Blocked Source, Open Question: What We Actually Know About DMT and Brain Repair
Every few months a study crosses my desk (or, more accurately, my group chat of retreat facilitators) claiming that DMT — the psychoactive molecule inside ayahuasca — does something remarkable to the brain. Grows new neurons. Sparks stem cells. Rewires trauma pathways. The screenshots fly around, the excitement builds, and then someone actually reads the paper and the picture gets more complicated. So let's slow down. If you're weighing an ayahuasca retreat because you've read that the brew might help with depression, addiction, or long-standing trauma, you deserve better than a shared headline. Here's what the research on DMT and neuroplasticity actually shows, what it doesn't, and how to think about it before you book anything. N,N-dimethyltryptamine is a small molecule that shows up all over the natural world — in plants, in animals, and, in trace amounts, in mammalian tissue including our own. In ayahuasca, DMT comes from the leaves of Psychotria viridis (or a similar admixture plant), while the Banisteriopsis caapi vine provides MAO inhibitors that let the DMT work orally. Without the vine, your gut breaks the DMT down before it reaches your brain. This is why ayahuasca is a brew and not a pill — the pharmacology is a two-plant partnership. Once DMT does reach the brain, it binds to serotonin receptors, particularly 5-HT2A, which is the same family of receptors that psilocybin and LSD hit. That receptor is doing a lot of interesting things beyond producing visuals. It's involved in learning, mood regulation, and — this is the part that keeps neuroscientists up at night — the growth of dendritic spines, the little branches that neurons use to talk to each other. Over the last several years, a handful of research groups have been publishing work suggesting that psychedelics, DMT included, promote what's called structural neuroplasticity. In lab dishes and in rodents, DMT appears to encourage neurons to grow new connections. Some recent studies have gone further, suggesting the molecule may also influence neural stem cells — the precursor cells that can, in theory, become new neurons. That's genuinely interesting. Depression, addiction, and PTSD are all associated with reduced neuroplasticity in specific brain regions — the prefrontal cortex, the hippocampus. If a compound can push those regions back toward growth mode, even briefly, it opens a real therapeutic window. This is the mechanism people are pointing to when they say psychedelics might help with the conditions that conventional treatment has failed on. But — and it's a meaningful but — most of this work is preclinical. That means Petri dishes and rodents, not humans in ceremony. The dose, delivery, and context of a lab study look nothing like a night in a maloca. Extrapolating from mouse brain slices to a decision about your own mental health is a leap. A defensible leap, maybe. But a leap. Here's where the science meets the actual decision you're making. If you're a person with depression that hasn't lifted after years of therapy and medication, or if you're trying to break the grip of an addiction, or if trauma keeps looping through your nervous system, the neuroplasticity research is a reason for cautious optimism. Not a promise. A reason. What the lab work suggests is that ayahuasca creates a window of heightened brain flexibility. During that window — which seems to last days to weeks after a ceremony — the mind is more open to forming new patterns. The old grooves aren't as deep. This is why serious facilitators talk endlessly about integration: the ceremony itself isn't the treatment. The treatment is what you do with the flexibility it creates. None of that requires the neuroscience to be settled. It just requires you to treat the retreat as one piece of a longer process, not a magic key. I don't want to hand you only the encouraging half. There are places where the DMT-and-neuroplasticity story is thinner than the enthusiasm around it. First, human trials on ayahuasca specifically are still small. There's promising work out of Brazil and Spain on ayahuasca for treatment-resistant depression, and a growing body of observational data on long-term users, but nothing at the scale of the psilocybin and MDMA trials. If you're waiting for the definitive study before you decide, you'll be waiting for years. Second, the neuroplasticity findings don't tell you anything about whether a specific retreat, run by a specific facilitator, in a specific setting, will actually help you. The molecule is one variable. Everything else — screening, dose, the person holding space, the group, your preparation, your aftercare — is the rest of the equation. Third, more plasticity isn't unambiguously good. A brain that's temporarily more malleable is also more suggestible. This is why context matters so much, and why the horror stories tend to come from places that put people into altered states without proper support. If your window of neural flexibility gets shaped by a chaotic, exploitative, or careless environment, that can leave marks too. Because more studies will drop, and more screenshots will circulate, here's a quick filter I use — and I'd suggest you use it too: None of this is to say the research is fake or the excitement is unearned. It's to say the honest position, right now, is that ayahuasca and DMT appear to do something real to the brain that overlaps with what people report subjectively — and we don't yet have the full picture. If you were already considering an ayahuasca retreat for reasons that felt personal — a stuck depression, an addiction you can't outthink, a trauma you can't outrun, or just an honest sense that something in your life needs to move — the neuroplasticity research is a supporting data point. It's not the reason to go, and its absence wouldn't be a reason to stay home. Traditional Amazonian practice has been using this brew for a very long time without needing a rodent study to justify it. If, on the other hand, you're being drawn in mostly by headlines about brain rewiring and stem cells, I'd gently push back. The molecule isn't the therapy. The therapy is what happens between you, the medicine, the people holding the space, and the weeks and months that follow. A great retreat with an honest facilitator will do more for you than a mediocre one, no matter what the neurons are up to. Do your due diligence. Talk to a doctor if you're on any serotonergic medications — the interaction with ayahuasca is real and non-trivial. Screen the retreat as hard as they should be screening you. And plan the aftercare before you plan the plane ticket. For readers who want to take this further, a range of vetted ayahuasca retreats can be browsed on our marketplace here. Read carefully, ask questions, and let the decision come from your own life rather than from a headline.
After the Ceremony: A Real Guide to Ayahuasca Integration
Ask anyone who has sat with ayahuasca more than once and they'll tell you the same thing: the ceremony is not the point. The ceremony is the door. What you do in the weeks and months after — how you sleep, who you talk to, what you cut out, what you finally sit down and look at — that's where the medicine actually earns its reputation. Integration is the unglamorous half of the story, and it's the half most retreat brochures skip. If you're reading this, there's a good chance you've either just come back from a retreat or you're weighing one. Maybe it's your first. Maybe it's your fifth, and the last one cracked open something you weren't expecting. Either way, the questions are the same. What now? Why does everything feel strange? Why did the insights feel so obvious in the maloca and so slippery two weeks later? Let's talk about it honestly. Integration is the process of translating whatever happened during a psychedelic experience into the way you live. That's it. It's not a certification, a workbook, or a Sunday call with a coach — though it can include those things. It's the daily, sometimes tedious work of noticing what the medicine showed you and letting that noticing change your behavior. People often confuse integration with interpretation. Interpretation is trying to figure out what the visions meant. Integration is what you do about the meaning. You can have a ceremony full of gorgeous symbolism and integrate none of it. You can have a ceremony that felt like nothing much and integrate a small, quiet realization into a completely different life. The showy nights aren't always the important ones. The hard truth: most of the people who don't get much lasting benefit from ayahuasca aren't the ones who had a bad experience. They're the ones who came home, put the experience in a mental scrapbook labeled “that time in Peru,” and returned to the same routines, the same relationships, the same coping habits. The medicine can point. It can't walk for you. The window right after a ceremony is when your nervous system is most porous. Old defenses are down. New patterns haven't hardened yet. What you feed yourself — food, media, conversation, sleep — lands harder than usual. Treat this stretch with more care than you think it deserves. A few things that consistently help: People vary wildly here. Some feel euphoric and expansive for a week. Others feel raw, tearful, or oddly flat. Both are normal. The plants often stir the sediment before the water settles — a stretch of low mood after a big ceremony doesn't mean it didn't work. Frequently it means the opposite. First-timers get the fireworks. The novelty alone is overwhelming — the taste, the icaros, the sheer strangeness of consciousness doing what it does under DMT. There's often a honeymoon quality. Big insights, big emotions, big sense of arrival. By the fourth or fifth ceremony, something shifts. The medicine tends to get quieter and more surgical. Less “cosmic download,” more “here is the specific thing you've been avoiding, and here it is again, and here it is again.” Repeat sitters often describe experienced ceremonies as boring, tedious, or frustratingly ordinary — right up until the moment they realize the ordinariness was the teaching. This is where integration gets harder, not easier. When ayahuasca stops giving you spectacle and starts giving you instructions, you have to actually follow them. The pattern you've been shown three ceremonies in a row — the way you shut down when your partner criticizes you, the drinking you're not really honest with yourself about, the career you keep half-choosing — becomes the whole assignment. Master plants have a way of repeating themselves until you listen. There's a whole cottage industry now around psychedelic integration and most of it is fine. Some of it is snake oil. Rather than endorse specific programs, here's what tends to help across the board, based on what long-term sitters actually do: Notice what's not on that list: booking another ceremony. Serial retreat-going is one of the more common integration failures. If the plants told you something in November and you haven't done anything about it by March, another ceremony in April isn't going to help. You'll usually get shown the same thing, louder. Sometimes it doesn't go smoothly. Sometimes people come back from a retreat and feel worse for weeks — anxious, unmoored, unable to sleep, flooded with old memories they weren't ready for. This is more common than the retreat industry likes to admit, and it's worth naming. Signs you need more support than a journal and a walk: persistent insomnia past two weeks, intrusive thoughts you can't shake, panic that shows up out of nowhere, dissociation, or a sense that reality feels thin or unreal. These are not necessarily signs the medicine harmed you — often they're signs that something was surfaced that needs a trained hand to help you work with. Reach out to a therapist who has experience with psychedelic aftercare. If your retreat center offered integration calls and you didn't take them, take them now. Plant medicine can be genuinely useful for addiction, depression, and trauma — and it can also destabilize people who weren't in the right place to sit. Neither of those things cancels the other out. Honest facilitators know this. If yours brushed off your post-ceremony struggles, take note for next time. The best measure of whether a ceremony worked isn't how you felt the next morning. It's how your life looks a year later. Did you actually leave the relationship? Did you actually stop the thing that was killing you slowly? Did you become someone your ten-year-old self would recognize as more themselves, not less? People who get real, durable benefit from ayahuasca tend to share a few habits. They treat ceremonies as rare rather than recreational. They spend as much time on the after as the during. They stay in some kind of community with others doing the same work. And they let the medicine change them in ways they didn't order in advance — including inconvenient ways. If you're at the stage of choosing where to sit, or where to sit next, pay attention to whether a retreat talks about integration at all before you arrive and after you leave. A curated selection of ayahuasca retreats — including centers that build integration support into the program — can be browsed on our marketplace here. The best ones treat the ceremony as the beginning of the work, not the end of it. That's the frame that tends to pay off.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
